Veracyte's revenue grew from $114.4M in Q2 2024 to $151.8M in Q3 2026, with year-over-year growth near 15% and gross margins holding around 70.6%, suggesting a durable and scalable diagnostics model.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.51+24.4% vs $0.41 | $152M+3.1% vs $147M |
Q3 2026 Jul 30, 2026 | $0.54+31.6% vs $0.41 | $150M+4.0% vs $145M |
Q2 2026 May 5, 2026 | $0.52+52.9% vs $0.34 | $139M+6.7% vs $130M |
Q1 2026 Feb 25, 2026 | $0.53+29.8% vs $0.41 | $141M+3.6% vs $136M |
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel Lauren Timmins - Jefferies LLC, Research Division Mason Carrico - Stephens Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Michael Matson - Needham & Company, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2026 Financial Results Conference Call.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS Global Healthcare Conference – Palm Beach Gardens, FLFireside chat on Tuesday, November 10 at 4:15 p.m.
Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benchmark VCYT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Veracyte, Inc. (VCYT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.16 | $1.93B | 15.77 | 16.01% | 21.8% | 9.27% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $78.56 | $4.06B | 33.58 | 13.79% | 25.86% | 34.08% | — | |
| $65.54 | $669.29M | 12.02 | 20.23% | 33.92% | 13.13% | 2.13% | |
| $32.96 | $1.34B | 13.14 | 17.12% | 6.67% | 27.44% | 1.44% | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — |
Veracyte, Inc. (VCYT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Veracyte, Inc. (VCYT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Jul 30, 2026·SEC
Jun 11, 2026·SEC
Get notified when VCYT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Veracyte, Inc. (VCYT) stock FAQ — growth, dividends, profitability & financials explained
Veracyte, Inc. (VCYT) reported $581.8M in revenue over the trailing twelve months. Revenue was $517.1M in fiscal year 2025. That is 19452% more than the $2.6M of fiscal year 2011.
Veracyte, Inc. (VCYT) grew revenue by 17.5% over the trailing twelve months, compared with the twelve months before.
Yes. Veracyte, Inc. (VCYT) earned $126.8M in net income over the trailing twelve months (a 21.8% net margin).
Veracyte, Inc. (VCYT) had a return on equity (ROE) of 9.3% over the trailing twelve months. That is below the market's typical 10-15%.
Veracyte, Inc. (VCYT) generated $161.4M in free cash flow over the trailing twelve months.
